Non-coding RNA biomarkers in basal-like breast cancer

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-05-31 DOI:10.1016/j.cca.2025.120408

Haider Ali , Nawaid Hussain Khan , Dalila Cano , Guadalupe Cano , Meliha Celik , Sama Lilo , Angel Fabia , Yama A. , Efrain Gudino , Beyza Nur Beker

{"title":"Non-coding RNA biomarkers in basal-like breast cancer","authors":"Haider Ali , Nawaid Hussain Khan , Dalila Cano , Guadalupe Cano , Meliha Celik , Sama Lilo , Angel Fabia , Yama A. , Efrain Gudino , Beyza Nur Beker","doi":"10.1016/j.cca.2025.120408","DOIUrl":null,"url":null,"abstract":"<div><div>Basal-like breast cancer (BLBC) is a highly aggressive molecular subtype characterized by poor prognosis and limited targeted treatment options. Clinicians face challenges in early diagnosis and precise prognostic stratification, necessitating the discovery of novel biomarkers and therapeutic targets. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), small interfering RNAs (siRNAs), and circular RNAs (circRNAs), have emerged as crucial regulators of breast luminal B cancer (BLBC) tumorigenesis and progression. Their subtype-specific expression and remarkable stability in body fluids make them promising candidates for minimally invasive biomarkers in clinical chemistry, enabling the early detection, prediction of prognosis, and monitoring of therapeutic response. Additionally, ncRNA-based therapeutics offer innovative strategies to overcome resistance and improve treatment efficacy. This review comprehensively synthesises the latest advances in understanding non-coding RNA (ncRNA) biology in breast luminal B-like cancer (BLBC), focusing on their roles in key oncogenic and tumour-suppressive pathways. We highlight the translational potential of ncRNAs as diagnostic and prognostic biomarkers and discuss emerging therapeutic applications alongside current challenges such as assay standardisation and delivery optimisation. The novelty of this review lies in its integrative approach, bridging molecular mechanisms with clinical implications to guide future research and clinical translation. We aim to provide a critical resource that supports the development of ncRNA-based precision medicine approaches to improve the management and outcomes of patients with basal-like breast cancer.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120408"},"PeriodicalIF":3.2000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125002876","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Basal-like breast cancer (BLBC) is a highly aggressive molecular subtype characterized by poor prognosis and limited targeted treatment options. Clinicians face challenges in early diagnosis and precise prognostic stratification, necessitating the discovery of novel biomarkers and therapeutic targets. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), small interfering RNAs (siRNAs), and circular RNAs (circRNAs), have emerged as crucial regulators of breast luminal B cancer (BLBC) tumorigenesis and progression. Their subtype-specific expression and remarkable stability in body fluids make them promising candidates for minimally invasive biomarkers in clinical chemistry, enabling the early detection, prediction of prognosis, and monitoring of therapeutic response. Additionally, ncRNA-based therapeutics offer innovative strategies to overcome resistance and improve treatment efficacy. This review comprehensively synthesises the latest advances in understanding non-coding RNA (ncRNA) biology in breast luminal B-like cancer (BLBC), focusing on their roles in key oncogenic and tumour-suppressive pathways. We highlight the translational potential of ncRNAs as diagnostic and prognostic biomarkers and discuss emerging therapeutic applications alongside current challenges such as assay standardisation and delivery optimisation. The novelty of this review lies in its integrative approach, bridging molecular mechanisms with clinical implications to guide future research and clinical translation. We aim to provide a critical resource that supports the development of ncRNA-based precision medicine approaches to improve the management and outcomes of patients with basal-like breast cancer.

查看原文本刊更多论文

基底样乳腺癌中的非编码RNA生物标志物

基底样乳腺癌（BLBC）是一种高度侵袭性的分子亚型，其特点是预后差，靶向治疗选择有限。临床医生在早期诊断和精确的预后分层方面面临挑战，需要发现新的生物标志物和治疗靶点。非编码rna (ncRNAs)，包括微rna （miRNAs）、长链非编码rna （lncRNAs）、小干扰rna （sirna）和环状rna (circRNAs)，已经成为乳腺癌B腔癌（BLBC）肿瘤发生和进展的重要调节因子。它们的亚型特异性表达和在体液中的显著稳定性使它们成为临床化学中微创生物标志物的有希望的候选者，能够早期检测、预测预后和监测治疗反应。此外，基于ncrna的治疗方法提供了克服耐药性和提高治疗效果的创新策略。本文综述了非编码RNA （ncRNA）在乳腺管腔b样癌（BLBC）中的最新生物学进展，重点介绍了它们在关键的致癌和肿瘤抑制途径中的作用。我们强调了ncrna作为诊断和预后生物标志物的转化潜力，并讨论了新兴的治疗应用以及当前的挑战，如检测标准化和递送优化。本综述的新颖之处在于其综合方法，将分子机制与临床意义联系起来，指导未来的研究和临床转化。我们的目标是提供一个关键资源，支持基于ncrna的精准医学方法的发展，以改善基底样乳腺癌患者的管理和预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.